Elif Şenocak Taşçı, Yasin Kutlu, Ömer Fatih Ölmez, Arda Ulaş Mutlu, Yasemin Gündoğdu, Mustafa Seyyar, Elif Şahin, Devrim Çabuk, Nargiz Majidova, İrem Uğurlu, Ayşe Demirci, Dinçer Aydın, Eyyüp Çavdar, Selami Bayram, Nilgün Yıldırım, Fatih Karataş, Melek Karakurt Eryılmaz, Dilek Çağlayan, Serkan Menekşe, Engin Kut, Hacı Arak, Murat Keser, Veli Sunar, Perihan Perkin, Teoman Şakalar, Başak Oyan, Özlem Sönmez, Leyla Özer, İbrahim Yıldız
BACKGROUND: Triple negative breast cancer (TNBC) is characterized by high rates of recurrence, especially in patients with residual disease after neoadjuvant chemotherapy (NAC). Capecitabine is being used as standard adjuvant treatment in residual TNBC. We aimed to investigate the real-life data regarding the efficacy of capecitabine in residual TNBC. DESIGN AND METHODS: In this retrospective multicenter study, TNBC patients with residual disease were evaluated...
April 3, 2024: Expert Opinion on Pharmacotherapy